市场调查报告书
商品编码
1496772
气喘药物市场:依产品、药物类别、给药途径- 全球预测 2024-2030Asthma Therapeutics Market by Product (Inhalers, Nebulizers), Drug Class (Anti-Inflammatory, Bronchodilators, Combination Therapy), Route of administration - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年气喘治疗市场规模为247亿美元,预计2024年将达272.6亿美元,2030年将达501亿美元,复合年增长率为10.63%。
气喘治疗市场包括与治疗和缓解气喘(一种慢性呼吸道疾病)症状的药物和治疗方法的研究、开发、生产和分销相关的所有活动。该市场服务于不同年龄层的不同患者群体,他们需要对气喘发作进行维持或急性治疗。市场范围包括多种治疗药物,如发炎药物、支气管扩张剂、联合治疗、生物製药以及吸入器和雾化器等输送装置。气喘药物市场的主要应用包括旨在维持病情稳定的长期治疗药物,以及针对急性症状的即时治疗药物。这些产品的最终用户通常是被诊断患有气喘的个人、肺科医生等医疗保健专业人员以及医院、诊所和居家照护机构等医疗保健机构。这也延伸到支援服务,例如病患教育和正确使用气喘管理设备的培训。由于气喘和其他呼吸系统疾病盛行率的增加、过敏检测和诊断技术的最新改进以及对单株抗体的广泛需求,对气喘治疗药物的需求正在增加。然而,气喘治疗市场面临着诸如气喘治疗设备的局限性和副作用、先进治疗的高成本以及偏远和农村地区的治疗覆盖范围有限等挑战。同时,气喘治疗市场正在出现一些商机,包括治疗联合治疗市场的开拓以及气喘治疗的广泛研发(R&D)。数位健康解决方案的趋势也在不断增长,例如可以追踪使用情况并提醒患者服药的智慧吸入器,从而为与科技和製药公司的合作提供了机会。
主要市场统计 | |
---|---|
基准年[2023] | 247亿美元 |
预测年份 [2024] | 272.6亿美元 |
预测年份 [2030] | 501亿美元 |
复合年增长率(%) | 10.63% |
区域洞察
美国气喘药物市场是由气喘高盛行率和强大的医疗基础设施所推动的。专利到期、新型生技药品和个人化医疗正在推动该地区的研究和创新。该地区的各个组织不断发现治疗方法并控制气喘、食物过敏、鼻过敏和其他过敏性疾病。南美洲对气喘治疗药物的需求正在增加,这主要是由于人们对呼吸系统疾病的认识提高和医疗设施的改善。欧洲是气喘药物的重要市场,并得到高认识、完善的医疗保健系统和有利的报销政策的支持。几个主要市场参与企业的存在以及对研发活动的重视也是值得注意的因素。德国、法国、瑞士、英国、法国和义大利等西欧国家占据主要市场占有率,而东欧国家则因医疗基础设施改善和气喘盛行率上升而显示出成长潜力。由于医疗基础设施的改善和私营部门投资的增加,中东市场正在不断发展。同时,非洲面临医疗服务有限、认知度低、获得治疗机会不足等挑战,阻碍了市场成长。然而,南非等某些国家在气喘治疗方面正在取得进展,这可能会对区域市场的开拓产生正面影响。在亚太地区,由于中阶的不断壮大和医疗改革的加强,中国的气喘治疗市场正在快速发展。在日本,患者可以获得一些最先进的治疗方法,反映出先进的医疗保健系统和患者的高度意识。日本的製药业具有高度创新性,拥有强大的新药研发管线以及持续的研发投资。印度气喘治疗市场的特点是需要负担得起的药物和加强气喘管理教育。由于人口众多和污染问题,气喘的盛行率正在增加。政府计画和非营利倡议旨在提高整个次大陆气喘治疗的可近性和可负担性。
FPNV定位矩阵
FPNV 定位矩阵对于评估气喘治疗药物市场供应商的市场定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对气喘治疗市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对公司目前在气喘药物市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[195 Pages Report] The Asthma Therapeutics Market size was estimated at USD 24.70 billion in 2023 and expected to reach USD 27.26 billion in 2024, at a CAGR 10.63% to reach USD 50.10 billion by 2030.
The asthma therapeutics market encompasses all activities related to the research, development, production, and distribution of medications and treatments designed to manage and alleviate the symptoms of asthma, a chronic respiratory disorder. This market serves a diverse population of patients across age groups who require either maintenance therapy or acute care for asthmatic episodes. The market scope includes various therapeutic products such as anti-inflammatory drugs, bronchodilators, combination therapies, biologics, and delivery devices such as inhalers and nebulizers. The primary applications within the asthma therapeutics market include long-term control medicines, which aim to maintain a stable condition, and quick-relief treatments for sudden symptoms. End-users of these products typically entail individuals diagnosed with asthma, healthcare professionals like pulmonologists, and healthcare settings, including hospitals, clinics, and homecare environments. The scope extends to support services like patient education and training on the proper use of asthma management devices. The need for asthma therapeutics is increasing due to growing incidences of asthma and other respiratory diseases, recent improvements in allergy detection and diagnostic technologies, and extensive demand for monoclonal antibodies. However, the asthma therapeutics market faces certain challenges, including limitations and side effects of asthma therapeutic devices, high costs associated with advanced treatments, and limited therapeutic reach in remote and rural areas. On the other hand, several opportunities are emerging within the asthma therapeutics market, including the development of combination therapeutics for the treatment and extensive research and development (R&D) efforts for asthma treatment. There is also an increasing trend towards digital health solutions, such as smart inhalers that can track usage and remind patients about doses, opening opportunities for tech companies and pharmaceutical partnerships.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 24.70 billion |
Estimated Year [2024] | USD 27.26 billion |
Forecast Year [2030] | USD 50.10 billion |
CAGR (%) | 10.63% |
Regional Insights
In the United States, the asthma therapeutics market is driven by a high prevalence of asthma alongside strong healthcare infrastructure. Patent expirations, novel biologics, and personalized medicine drive research and innovation in the region. Various organizations in the region continue to find a cure for and control asthma, food allergies, nasal allergies, and other allergic diseases. South America shows a growing need for asthma therapeutics, largely due to increasing awareness of respiratory diseases and improving healthcare facilities. Europe represents a substantial market for asthma therapeutics, supported by high awareness levels, established healthcare systems, and favorable reimbursement policies. The presence of several key market players and a strong emphasis on research and development activities are notable factors. Western European countries, including Germany, France, Switzerland, the United Kingdom, France, and Italy, hold a major market share, while Eastern European countries exhibit potential for growth due to improving healthcare infrastructure and rising asthma prevalence. The market in the Middle East is advancing with the development of healthcare infrastructure and increasing private sector investment. In contrast, Africa faces challenges such as limited healthcare services, low awareness, and inadequate access to treatment, which hinder market growth. However, certain countries, including South Africa, are making strides in asthma care, which can positively influence regional market development. In APAC, China's asthma therapeutic market is developing rapidly due to the growing middle class and enhanced healthcare reforms. In Japan, patients have access to several state-of-the-art treatments, reflecting the country's advanced healthcare system and high patient awareness. Japan's pharmaceutical sector is highly innovative, with a robust pipeline of new drugs and consistent investment in R&D. India's asthma treatment market is characterized by a need for affordable medications and increased education on asthma management. The high population, coupled with pollution issues, contributes to a growing prevalence of asthma. Government programs and non-profit initiatives aim to enhance asthma care accessibility and affordability throughout the subcontinent.
Market Insights
The market dynamics represent an ever-changing landscape of the Asthma Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Asthma Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Asthma Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
GSK Boosts Respiratory Portfolio with $1.4 Billion Aiolos Bio Acquisition
GlaxoSmithKline PLC has announced the acquisition of Aiolos Bio Inc. with an investment of USD 1.4 billion. This acquisition aims to enhance GSK's foothold in the asthma treatment market as this deal gives GSK access to AIO-001, a cutting-edge asthma therapy by Aiolos Bio. [Published On: 2024-01-09]
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
Teva Pharmaceutical Industries Ltd. and Biolojic Design Ltd. announced an exclusive license agreement to develop a potential novel antibody-based therapy for treating Atopic Dermatitis and Asthma. BD9 is novel for its dual-action mechanism that inhibits both TSLP and IL-13, offering a more comprehensive treatment option over current single-target therapies. This collaboration is a strategic move complementing Teva's 'Pivot to Growth' strategy, which was unveiled in May 2023 and focuses on stoking innovation through partnerships and enhancing Teva's early-stage pipeline. [Published On: 2023-12-14]
Lupin Launches Luforbec(R) 100/6 for Adult Asthma and COPD Treatment
Hormosan Pharma GmbH, a fully owned subsidiary of Lupin Limited, announced the launch of Luforbec 100/6, a fixed blend in a pressurized metered dose inhaler (pMDI) for the remedy of adult chronic obstructive pulmonary disease (COPD) and asthma in Germany. [Published On: 2023-09-26]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Asthma Therapeutics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Asthma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Chiesi Farmaceutici S.p.A., Cipla Limited, F. Hoffmann-La Roche Ltd, Genentech, Inc., GlaxoSmithKline PLC, Kare Medical and Analytical Devices Ltd. Co., Koninklijke Philips N.V., Lupin Limited, Medtronic PLC, Merck & Co, Inc., Merxin Ltd., Novartis AG, Parekhplast India Limited, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Shenzhen Aeon Technology Co., Ltd., Softhale NV by invoX Pharma Limited, Sun Pharmaceutical Industries Limited, Sunovion Pharmaceuticals, Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Trudell Medical Limited, Viatris Inc., and Wellinks, Inc..
Market Segmentation & Coverage